Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pharvaris N.V. (PHVS : NSDQ)
 
 • Company Description   
Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated indications. Pharvaris N.V. is based in ZUG, Switzerland.

Number of Employees: 108

 
 • Price / Volume Information   
Yesterday's Closing Price: $17.60 Daily Weekly Monthly
20 Day Moving Average: 43,215 shares
Shares Outstanding: 52.29 (millions)
Market Capitalization: $920.31 (millions)
Beta: -2.82
52 Week High: $25.50
52 Week Low: $11.51
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 6.73% 2.10%
12 Week 33.23% 8.70%
Year To Date -8.19% -12.97%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
EMMY NOETHERWEG 2
-
LEIDEN,P7 2333
NLD
ph: 31-71-203-6410
fax: -
info@pharvaris.com http://www.pharvaris.com
 
 • General Corporate Information   
Officers
Berndt Modig - Chief Executive Officer and Executive Director
David Nassif - Chief Financial Officer
Hans Schikan - Director
David Meeker - Director
Viviane Monges - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N69605108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 52.29
Most Recent Split Date: (:1)
Beta: -2.82
Market Capitalization: $920.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.87 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.47 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 11.31% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.88
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -58.93%
vs. Previous Quarter: -30.88%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -54.02
12/31/24 - -42.61
ROA
06/30/25 - -
03/31/25 - -50.36
12/31/24 - -40.13
Current Ratio
06/30/25 - -
03/31/25 - 11.10
12/31/24 - 12.60
Quick Ratio
06/30/25 - -
03/31/25 - 11.10
12/31/24 - 12.60
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 4.54
12/31/24 - 5.54
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.24
12/31/24 - 0.24
 

Powered by Zacks Investment Research ©